Jennifer Chao
Ophthalmology · Seattle, WANPI 1902002736
Payments from drug & device makers
What this record shows
This record is dominated by grants: $187,500 of the $187,657 with a category attached, or 99.9%. Alcon Research LLC accounts for 99.9% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2020 at $187,500 and has fallen 99.9% since, to $95 in 2023. Among ophthalmology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 3 payments — averaging $62,552 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon Research LLC$188K
- Bausch & Lomb Americas Inc.$95
- Alcon$62
Across 1 payment — averaging $24,049 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astellas Pharma Global Development$24K
What the payments were for
- Grants$187,500100%
- Food & beverage$1570%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon Research LLC | 1 | $187,500 |
| Bausch & Lomb Americas Inc. | 1 | $95 |
| Alcon | 1 | $62 |
How this compares
$187,657 in reported general payments places this provider in the 95th percentile of 428 ophthalmology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dorzolamide Hcl | 14 | $205 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Seattle
- Laura PerimanSeattle$1.7M
- Sheldon CowenSeattle$560K
- Debarshi MustafiSeattle$85K
- Michelle CabreraSeattle$75K
- Paul GriggsSeattle$62K
- Lisa Olmos de KooSeattle$50K
- Kathryn PeppleSeattle$29K
- Yewlin CheeSeattle$23K
- Miel SundararajanSeattle$12K
- Brant CarrollSeattle$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.